Pfizer, Flynn, UK antitrust regulator prevail in drug-pricing judgment appeals
( June 19, 2026, 12:42 GMT | Official Statement) -- MLex Summary: Drugmakers Pfizer and Flynn Pharma as well as the UK Competition and Markets Authority have all won their appeals against a November 2024 ruling by the Competition Appeal Tribunal over an epilepsy-drug pricing case. The Court of Appeal judgment comes in a case that stemmed from the drug companies being fined by the CMA in 2022 for abuse of dominance over having greatly increased the price of phenytoin sodium capsules over a number of years without justification. They appealed the decision to the CAT, which in its 2024 judgment set aside the decision but remade it, also concluding that Pfizer and Flynn were guilty. All parties then appealed.Ruling attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.